DEFINITIVE CONTRACT
Active75F40126C00223
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$498.1K
obligated · signed 6 days ago
SUPPORT FOR RARE DISEASE INNOVATION HUB
Performance timeline
Start
Sep 30, 2026
Current end
Sep 29, 2027
Potential end
Mar 26, 2029
with all options
Loading status
Estimated start: Mar 26, 2028
LANEVIS, L.L.C
Contract 75F40126C00223
UEI
UJSBWLVVB5K7
Parent Company
LANEVIS, L.L.C
Capabilities & Certifications
Headquarters Location
Congressional District: 90
Current Obligation
$498,100
Base + Exercised Options
$498,100
Total Ceiling Value
$1,478,036
Contract Type
LABOR HOURS
Multi-Year Contract
NO
NAICS
COMPUTER SYSTEMS DESIGN SERVICES
PSC
IT AND TELECOM - BUSINESS APPLICATION/APPLICATION DEVELOPMENT SOFTWARE AS A SERVICE
Place of Performance
Congressional District: 08
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.